Browse Amazon

Valid XHTML 1.0!

Valid CSS!

Publications

Articles, papers and letters by Anthony Cox. Links given when available.

Publications

Cox AR, Langford N. Drug-induced cardiac failure. Adverse Drug Reaction Bulletin. 2003;220:843-846.

Anton C, Cox AR, Watson RDS, Ferner RE. The safety of spironolactone treatment in patients with heart failure. Journal of Clinical Pharmacy & Therapeutics. 2003;28(4):285-287. [Abstract]

Cox AR, The war on the web: Googlebomb of mass destruction. The Guardian. 10th July 2003. [text]

Kerr KL, Higham C, Cox AR, Situnayake RD. A determination of patient awareness of the safety issues surrounding treatment with methotrexate. The Pharmaceutical Journal 2003;271:900-901. [PDF]

Cox AR. Let us be called the Royal Society of Pharmacists of Great Britain. The Pharmaceutical Journal 2003;271:44. [text] [PDF]

Cox AR. Manufacturers should make reading labels easier. The Pharmaceutical Journal 2003;270:514. [text]

Cox AR, Anton C. Report [...] drug reactions with warfarin. The Pharmaceutical Journal 2003;270:366-367. [text]

Cox AR. Advertising: Prescribers need appraisal training programmes. The Pharmaceutical Journal 2003;270:154. [text]

Whitaker S, Cox AR, Alexander AM. Internet networking for pharmacists: an evaluation of a mailing list for UK pharmacists. International Journal of Pharmacy Practice. 2003;11:25–32. [Abstract]

Anton CA, Cox AR, Ferner RE. Using trade names: sometimes it helps. Archives of Internal Medicine 2003 ; 162 : 2636.

Cox AR, Dent SN. Warfarin: Risks not always easy to evaluate. British Medical Journal Electronic response [text]

Anton C, Cox AR. More data are needed. British Medical Journal Electronic response [text]

Dent SN, Cox AR, Marriott JF, Langley CA, Wilson KA. Warfarin toxicity: do discharge ICD-codes and yellow cards accurately identify serious adverse drug reactions? The International Journal of Pharmacy Practice. 2002; 10(suppl) :R40. [PDF]

Cox AR. Systemic effects of ocular drugs. Adverse Drug Reaction Bulletin. 2002; 215 :823-826.

Langford NJ, Cox AR. Medication errors: Over reliance on any safety system is not ideal. The Pharmaceutical Journal. 2002; 269 :248. [text]

Rippengill KL, Higham C, Cox Ar, Situnayake RD. Methotrexate - patient awareness and safety issues. Pharmacy World & Science. 2002; 24(3) :A21.

Cox AR. Embracing ADR reporting could improve pharmacists' standing. The Pharmaceutical Journal 2002; 269 :14. [text] [PDF]

Cox A, Jenkins A. A case of carboplatin hypersensivity. Pharmacy in Practice 2002; 12(5) :187.

Cox A, Millane T. An adverse drug reaction as a consequence of error. Pharmacy in Practice 2002; 12(2) :84-86.

Cox AR, Marriott JF. Take a spoonful of sugar with salt. The Hospital Pharmacist 2002; 9(4) :90. [text]

Cox A. Childhood vaccination, a social responsibility. The Pharmaceutical Journal 2002; 268 :570. [text]

Cox A, Book Review - Martindale 33rd edition. The Pharmaceutical Journal 2002; 268 :505. [text]

Cox A, Overwhelming evidence for safety of MMR. The Pharmaceutical Journal 2002; 268 :398. [text]

Cox AR. Marriott JF. Safety First. Pharmaceutical Marketing February 2002 [text]

Jenkins A, Cox A. Influenza vaccine and warfarin. Pharmacy in Practice 2002; 12(1) :140.

Cox A. Humans are fallible machines. British Medical Journal Electronic response [text]

Cox A. Syncope as a possible adverse drug reaction. Pharmacy in Practice 2001; 11(9) :286.

Cox A, Underhill J. New Drugs must be prescribed judiciously. The Pharmaceutical Journal 2001; 267 :646-647. [text]

Cox A. What about side effects and contraindications? The Pharmaceutical Journal 2001; 267 :425. [text]

Cox A, Anton C. Safety profile of bupropion for chronic obstructive pulmonary disease. The Lancet 2001; 358 :1010.

Cox A, Anton C, Goh CHF, Easter M, Langford NJ, Ferner RE. Adverse drug reactions in patients admitted to hospital indentified by discharge ICD-10 codes and by spontaneous reports. British Journal of Clinical Pharmacology 2001; 52 :337-339.

Bradley M.J, Cox A. Suspected interaction betweeen celecoxib and warfarin. Pharmacy in Practice 2001; 11(8) :243-245.

Anton C, Cox A. In some respects, yes. British Medical Journal Electronic response [text]

Anton C, Cox A. Adverse Drug reactions. British Journal of General Practice. 2001; 51(468) :582-683. [text]

Cox A, Anton C, Ferner R. Take care with Zyban. The Pharmaceutical Journal. 2001; 266 :718-722. [text]

Cox AR, Marriott J. Is self-checking (by anyone) a risk too far? The Pharmaceutical Journal 2001; 266 :814. [text]

Cox AR. Hypokalaemia associated with the use of spironolactone in heart failure. Pharmacy in Practice. 2001; 11(6) :187-189.

Cox AR, Barnett AL. Reporting reactions to newly marketed drugs. Pharmacy in Practice. 2001; 11(4) :121-122.

Mundia AN, Cox AR, Marriott JF. Discordance: coronary care patient's knowledge of Medicines. GHP . 2001; 2(2) :14.

Cox AR. What can hospital pharmacy do to increase adverse drug reaction reporting. Pharmacy in Practice . 2001; 11(3) :84.

Cox AR. Haematoma associated with tirofiban and enoxaparin in an unstable angina patient. Pharmacy in Practice . 2001; 11(3) :87-88.

Cox AR. Adverse reactions to intra-vascular radiological contrast media. Pharmacy in Practice . 2001; 11(2) :54-55.

Cox AR, McCarthy J. Hepatic adverse drug reactions. Pharmacy in Practice. 2000; 11(1) :18-19.

Cox AR, Fox H. Split and merge: a way forward for the Royal Pharmaceutical Society. The Pharmaceutical Journal 2000; 265 :263. [text]

Cox AR, Barrett J. Identifying adverse drug reactions in the ICU. Pharmacy in Practice . 2000; 10(9) : 322-4.

Cox AR, Townsend T. Reporting well-known reactions. Pharmacy in Practice. 2000; 10(8) : 288-90.

Cox AR. Elite II: Caution required The Pharmaceutical Journal. 2000; 263 :858. [text]

Cox AR. The pharmacist's role in adverse drug reactions. Pharmacy in Practice . 2000; 10(7) : 262-3.

Cox AR. The Committee on Safety of Medicine's Yellow Card Scheme. Pharmacy in Practice. 2000; 10(6) : 213-15.

Cox AR, Marriott J. Dealing with dispensing errors. The Pharmaceutical Journal . 2000; 264 :724. [text]

Cox AR. Pharmacovigilance: Why reports are anonymous The Pharmaceutical Journal. 1999; 263 :784. [text]

Other articles and letters

Cox AR. The Society: Membership approval The Pharmaceutical Journal. 2003; 271 :175. [text]

Cox AR. An opportunity to move forward. The Pharmaceutical Journal. 2003; 270 :858. [text]

Cox A. The Society: Knocking down a straw man The Pharmaceutical Journal. 2002; 269 :100. [text]

Cox A. A way forward for the Society? Pharmacy Magazine. 2002; June issue :8

Cox A. Time to bring clarity to the representation debate The Pharmaceutical Journal. 2002; 268 :140. [text]

Cox A. Access to reports of the statutory committee. . The Pharmaceutical Journal. 2001; 267 :321-324. [text]

Cox A. Leadership requires listening. The Pharmaceutical Journal. 2001; 266 :852-856. [text]

Fox HR,Cox AR. Some changes are inevitable. The Pharmaceutical Journal. 2001; 265 :855. [text]

Cox AR. Finance concern. The Pharmaceutical Journal. 2000; 265 :754. [text]

Cox AR. Parish Magazine. The Pharmaceutical Journal. 2000; 265 :443. [text]

Fox HR, Cox AR. Separation of functions . The Pharmaceutical Journal. 2000; 265 :394. [text]

Cox AR. e-pharmacy: ethereal pharmacy? Chemist and Druggist 2000; 30 September 2000 :8

Whitaker S, Cox AR, Alexander AM The members, the medium and the message: an evaluation of Private-Rx, the information network for UK pharmacists. The Pharmaceutical Journal 2000; 265 :R73. (suppl British Pharmaceutical Conference, Birmingham) [text]

Cox AR. Breaking the deadlock. The Pharmaceutical Journal. 2000; 265 :363. [text]

Cox AR, Whitaker S. Protecting the legacy. The Pharmaceutical Journal. 2000; 265 :160. [text]

Cox AR. Cat Mat Publicity The Pharmaceutical Journal. 2000; 264 :655. [text]

Nebrensky C, Cox AR, Burgess P, Haynes S, Wong LS, Young J, et al.. Who authorised flat purchase? The Pharmaceutical Journal. 2000; 264 :589. [text]

Phillips G, Cox AR, Eyles R, Fox H, Whitaker S, Curtis S, et al.. More details please The Pharmaceutical Journal. 2000; 264 :402-403. [text]

Cox AR. Electing the Council The Pharmaceutical Journal. 1999; 263 :349. [text]